92 related articles for article (PubMed ID: 26572413)
41. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
42. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Yao Y; Su Z; Liang Y; Zhang N
Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
[TBL] [Abstract][Full Text] [Related]
43. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Pennarun B; Kleibeuker JH; Boersma-van Ek W; Kruyt FA; Hollema H; de Vries EG; de Jong S
J Pathol; 2013 Feb; 229(3):410-21. PubMed ID: 23132258
[TBL] [Abstract][Full Text] [Related]
44. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
45. Poloxamer surface modified trimethyl chitosan nanoparticles for the effective delivery of methotrexate in osteosarcoma.
Li S; Xiong Y; Zhang X
Biomed Pharmacother; 2017 Jun; 90():872-879. PubMed ID: 28449430
[TBL] [Abstract][Full Text] [Related]
46. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.
Wang CF; Mäkilä EM; Kaasalainen MH; Liu D; Sarparanta MP; Airaksinen AJ; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Jan; 35(4):1257-66. PubMed ID: 24211082
[TBL] [Abstract][Full Text] [Related]
47. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
48. Enhancement of the targeting capabilities of the Paclitaxel-loaded pluronic nanoparticles with a glycol chitosan/heparin composite.
Yuk SH; Oh KS; Cho SH; Kim SY; Oh S; Lee JH; Kim K; Kwon IC
Mol Pharm; 2012 Feb; 9(2):230-6. PubMed ID: 22149139
[TBL] [Abstract][Full Text] [Related]
49. Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
Zhang JY; He B; Qu W; Cui Z; Wang YB; Zhang H; Wang JC; Zhang Q
J Microencapsul; 2011; 28(6):528-36. PubMed ID: 21702701
[TBL] [Abstract][Full Text] [Related]
50. Sorafenib-Loaded Ligand-Functionalized Polymer-Lipid Hybrid Nanoparticles for Enhanced Therapeutic Effect Against Liver Cancer.
Tang S; Li Y
J Nanosci Nanotechnol; 2019 Nov; 19(11):6866-6871. PubMed ID: 31039838
[TBL] [Abstract][Full Text] [Related]
51. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
52. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
53. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.
Elzeny H; Zhang F; Ali EN; Fathi HA; Zhang S; Li R; El-Mokhtar MA; Hamad MA; Wooley KL; Elsabahy M
Drug Des Devel Ther; 2017; 11():483-496. PubMed ID: 28260861
[TBL] [Abstract][Full Text] [Related]
54. An investigation of antitumor efficiency of novel sustained and targeted 5-fluorouracil nanoparticles.
Le VM; Wang JJ; Yuan M; Nguyen TL; Yin GF; Zheng YH; Shi WB; Lang MD; Xu LM; Liu JW
Eur J Med Chem; 2015 Mar; 92():882-9. PubMed ID: 25676729
[TBL] [Abstract][Full Text] [Related]
55. Dual-functional bio-derived nanoparticulates for apoptotic antitumor therapy.
Ding Y; Wang Y; Opoku-Damoah Y; Wang C; Shen L; Yin L; Zhou J
Biomaterials; 2015 Dec; 72():90-103. PubMed ID: 26344366
[TBL] [Abstract][Full Text] [Related]
56. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.
Guo Y; Zhong T; Duan XC; Zhang S; Yao X; Yin YF; Huang D; Ren W; Zhang Q; Zhang X
Drug Deliv; 2017 Nov; 24(1):270-277. PubMed ID: 28165798
[TBL] [Abstract][Full Text] [Related]
57. RGD Peptides-Conjugated Pluronic Triblock Copolymers Encapsulated with AP-2α Expression Plasmid for Targeting Gastric Cancer Therapy in Vitro and in Vivo.
Wang W; Liu Z; Sun P; Fang C; Fang H; Wang Y; Ji J; Chen J
Int J Mol Sci; 2015 Jul; 16(7):16263-74. PubMed ID: 26193262
[TBL] [Abstract][Full Text] [Related]
58. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Wang Z; Duan X; Lv Y; Zhao Y
Life Sci; 2019 Dec; 239():117013. PubMed ID: 31678287
[TBL] [Abstract][Full Text] [Related]
59. Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
Shi L; Hu Y; Lin A; Ma C; Zhang C; Su Y; Zhou L; Niu Y; Zhu X
Bioconjug Chem; 2016 Dec; 27(12):2943-2953. PubMed ID: 27998073
[TBL] [Abstract][Full Text] [Related]
60. Biosynthesis of sorafenib coated graphene nanosheets for the treatment of gastric cancer in patients in nursing care.
Xu X; Tang X; Wu X; Feng X
J Photochem Photobiol B; 2019 Feb; 191():1-5. PubMed ID: 30557787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
